Work

Cancer-control outcomes of metastatic castration resistant prostate cancer patients with BRCA -gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.71

Authors: Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Henning Reis, Peter Wild, Thomas Steuber, Markus Graefen, Derya Tilki, Amir Sabet, Daniel Groener, Felix Chun, Philipp Mandel

Institutions: University Hospital Frankfurt, Goethe University Frankfurt, Universität Hamburg, University Medical Center Hamburg-Eppendorf, Martini-Klinik

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407699398

Cites:

Cited by:

Related to: 10